Fmoc-Val-Ala-PAB-OH 是一种有用的接头，可用于制备用于靶向药物递送的抗体-药物偶联物??。它还用于合成带有溶酶体可切割接头的 RGD 拟肽-紫杉醇缀合物。

Fmoc-Val-Ala-PAB is a useful linker for making Antibody-Drug-Conjugation (ADC) conjugate for targeting drug delivery. It is also utilized in the synthesis of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.

Osilodrostat and pasireotide monotherapies can significantly affect in the histology and mean weights of the pituitary and adrenal glands, liver, and ovary/oviduct. Osilodrostat is associated with adrenocortical hypertrophy and hepatocellular hypertrophy. The combination of Osilodrostat with pasireotide ameliorates the liver and adrenal gland changes observed with monotherapy and does not exacerbate any target organ changes. Cmax and AUC(0–24h) of Osilodrostat and pasireotide increase in an approximately dose-proportional manner. Osilodrostat treatment reduces urinary free cortisol in patients with Cushing's disease; 78.9% has normal urinary free cortisol at week 22.

1394238-91-5

C30H33N3O5

515.61

Fmoc-Val-Ala-PAB;Fmoc-Val-Ala-PAB-OH

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years